Jazz Pharma EVP Pearce sold 6,907 shares at $235.41; 50.3K shares remain post-transaction
Samantha Pearce, EVP and Chief Commercial Officer, sold 6,907 shares (6.9K shares) of Jazz Pharmaceuticals plc (JAZZ) at $235.41 on 2026-05-28 for total value of $1,625,976.87 ($1.6M), reducing her shareholding from 57,179 shares (57.2K shares) to 50,272 shares (50.3K shares), a -12.1% reduction in that portion of her holdings. The sale occurred at $235.41, which is within the 52-week range of $105.00–$243.32 and represents -4.4% from the 52-week high; the stock has appreciated +14.8% over 30 days and +24.6% over 90 days, indicating recent momentum. The company reported revenue of $1,068,900,000.00 ($1.1B) in the latest quarter with net income of $293,100,000.00 ($293.1M), though it was unprofitable over its most recent full fiscal year, and carries a notably elevated P/E of 494.98 relative to the trailing net income metric. The insider retains 50,272 shares (50.3K shares) of non-derivative holdings and maintains no non-qualified stock options, indicating a partial reduction rather than a full position exit.